Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Long-Term Investments for 9 consecutive years, with $24.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments fell 94.45% to $24.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.7 million, a 94.45% decrease, with the full-year FY2024 number at $359.4 million, changed N/A from a year prior.
  • Long-Term Investments was $24.7 million for Q3 2025 at Denali Therapeutics, down from $78.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $490.7 million in Q1 2024 to a low of $7.9 million in Q3 2023.
  • A 5-year average of $236.7 million and a median of $243.1 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 5535.21% in 2024, then crashed 94.45% in 2025.
  • Denali Therapeutics' Long-Term Investments stood at $425.4 million in 2021, then crashed by 77.85% to $94.2 million in 2022, then crashed by 91.61% to $7.9 million in 2023, then skyrocketed by 4446.15% to $359.4 million in 2024, then plummeted by 93.13% to $24.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Long-Term Investments are $24.7 million (Q3 2025), $78.5 million (Q2 2025), and $235.8 million (Q1 2025).